57 related articles for article (PubMed ID: 21703195)
1. Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis.
Deltenre P; Louvet A; Lemoine M; Mourad A; Fartoux L; Moreno C; Henrion J; Mathurin P; Serfaty L
J Hepatol; 2011 Dec; 55(6):1187-94. PubMed ID: 21703195
[TBL] [Abstract][Full Text] [Related]
2. Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis.
Cammà C; Cabibbo G; Bronte F; Enea M; Licata A; Attanasio M; Andriulli A; Craxì A
J Hepatol; 2009 Oct; 51(4):675-81. PubMed ID: 19665247
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis: insulin resistance and sustained virological response in hepatitis C.
Eslam M; Aparcero R; Kawaguchi T; Del Campo JA; Sata M; Khattab MA; Romero-Gomez M
Aliment Pharmacol Ther; 2011 Aug; 34(3):297-305. PubMed ID: 21623851
[TBL] [Abstract][Full Text] [Related]
4. Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients.
Guzmán-Fulgencio M; Jiménez JL; Berenguer J; Fernández-Rodríguez A; López JC; Cosín J; Miralles P; Micheloud D; Muñoz-Fernández MÁ; Resino S
J Antimicrob Chemother; 2012 May; 67(5):1238-45. PubMed ID: 22294644
[TBL] [Abstract][Full Text] [Related]
5. Sustained virological response following chronic hepatitis C treatment is associated with improvement in insulin resistance.
Chan CH; Hansen RD; Gilliver RS; Jones BE
Intern Med J; 2013 Jun; 43(6):656-62. PubMed ID: 23506416
[TBL] [Abstract][Full Text] [Related]
6. Insulin resistance as a predictor of early virologic response to HCV therapy among chronic HCV Egyptian patients.
Abd El-Wahab EW; Mikheal A; Sidkey F; Shatat HZ
J Med Virol; 2015 Mar; 87(3):428-40. PubMed ID: 25583244
[TBL] [Abstract][Full Text] [Related]
7. Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial.
Younossi Z; Negro F; Serfaty L; Pol S; Diago M; Zeuzem S; Andreone P; Lawitz EJ; Roberts S; Focaccia R; Foster GR; Horban A; Lonjon-Domanec I; Coate B; DeMasi R; Picchio G; Witek J
Hepatology; 2013 Dec; 58(6):1897-906. PubMed ID: 24382638
[TBL] [Abstract][Full Text] [Related]
8. The association of hepatitis c virus infection status with serum glucose levels.
Li Y; Wang X; Yu G; Sun H; Lv J; Chi X; Wu R; Gao X; Niu J
BMC Gastroenterol; 2019 Jun; 19(1):86. PubMed ID: 31195990
[TBL] [Abstract][Full Text] [Related]
9. HCV infection, HOMA index and sustained virological response: the step we need to take before moving forward.
La Mura V; Persico M
J Hepatol; 2012 Aug; 57(2):472; author reply 473. PubMed ID: 22387670
[No Abstract] [Full Text] [Related]
10. HCV treatment with direct acting antivirals improves the insulin sensitivity.
Alsebaey A; Elhelbawy M; Abdel-Razek W; Hashim M; Elshenawy H; Waked I
Expert Rev Anti Infect Ther; 2019 Sep; 17(9):749-754. PubMed ID: 31393188
[No Abstract] [Full Text] [Related]
11. Clearance of HCV by Combination Therapy of Pegylated Interferon alpha-2a and Ribavirin Improves Insulin Resistance.
Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
Gut Liver; 2009 Jun; 3(2):108-15. PubMed ID: 20431732
[TBL] [Abstract][Full Text] [Related]
12. Study of prevalence and effects of insulin resistance in patients with chronic hepatitis C genotype 4.
Amer AF; Baddour MM; Elshazly MA; Fadally G; Hanafi NF; Assar SL
East Mediterr Health J; 2016 Feb; 21(11):803-10. PubMed ID: 26857717
[TBL] [Abstract][Full Text] [Related]
13. Insulin resistance and response to telaprevir plus pegylated interferon and ribavirin: a requiem for the HOMA score?
Aghemo A; Colombo M
Gastroenterology; 2012 Dec; 143(6):1685-7. PubMed ID: 23073135
[No Abstract] [Full Text] [Related]
14. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Heathcote EJ; Manns MP; Kuske L; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
JAMA; 2012 Dec; 308(24):2584-93. PubMed ID: 23268517
[TBL] [Abstract][Full Text] [Related]
15. Metabolic aspects of hepatitis C virus.
El-Kassas M; Awad A
World J Gastroenterol; 2022 Jun; 28(22):2429-2436. PubMed ID: 35979265
[TBL] [Abstract][Full Text] [Related]
16. Does Hepatitis C Virus Treatment by Directly Acting Antivirals Obligate Shifting Patients with Type 2 Diabetes from Oral Hypoglycemic Drugs to Insulin Therapy?
Hagag RY; Selim AF; Darrag OM; Zied H; Aboelnasr MS
Diabetes Metab Syndr Obes; 2022; 15():1261-1268. PubMed ID: 35502409
[TBL] [Abstract][Full Text] [Related]
17. Metabolic complications of hepatitis C virus infection.
Chaudhari R; Fouda S; Sainu A; Pappachan JM
World J Gastroenterol; 2021 Apr; 27(13):1267-1282. PubMed ID: 33833481
[TBL] [Abstract][Full Text] [Related]
18. Effect of HCV treatment response on insulin resistance: A systematic review and meta-analysis.
Hu JH; Chang ML; Liu NJ; Yeh CT; Huang TJ
Exp Ther Med; 2019 Nov; 18(5):3568-3578. PubMed ID: 31602234
[TBL] [Abstract][Full Text] [Related]
19. Predicting the response to the treatment of hepatitis C virus infection.
Thomas DL
Clin Liver Dis (Hoboken); 2012 Apr; 1(2):46-48. PubMed ID: 31186846
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
